In pulmonary disease, which drug is conditionally recommended?

• A. Leflunomide
• B. Methotrexate
• C. TNF inhibitors
• D. Hydroxychloroquine

Answer: (B)

In patients with pulmonary disease, treatment decisions for inflammatory or dermatologic conditions must balance how well a drug works with the potential for lung-related toxicity. Methotrexate fits as a conditional choice because it has strong and broad effectiveness for inflammatory skin diseases and related systemic involvement, and it is a well-established option with a manageable safety profile when patients are carefully monitored. The concern with methotrexate is the possibility of MTX-induced pneumonitis, which means clinicians need to screen for lung issues and watch for cough, dyspnea, fever, or new respiratory symptoms, adjusting therapy if needed.

Other options carry more apparent risks for the lungs in this context. TNF inhibitors can be associated with worsening interstitial lung disease or infection risk, making them less favorable when lung disease is already present. Leflunomide also has a documented risk of lung toxicity and interstitial disease. Hydroxychloroquine is relatively safer for the lungs but may not provide sufficient control of more severe inflammatory disease on its own. Therefore, methotrexate is recommended only if the expected benefits outweigh the pulmonary risks and with vigilant monitoring.